Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

Subjects will receive oral avatrombopag once daily for 5 days beginning on Day 1, followed by
a wait period prior to the procedure, which will occur on Day 10 to 13. The Follow-up Period
will include 2 visits; 7 days post-procedure and 30 days after last dose.

Inclusion Criteria:

- Men and women greater than or equal to 18 years of age;

- A mean baseline platelet count between:

- 50 × 10^9/L and <100 × 10^9/L for non-chronic liver disease participants

- 50 × 10^9/L and <75 × 10^9/L for participants with chronic liver disease;

- Participant is scheduled to undergo operations to critical sites (eg, eye surgery,
neurosurgery) or operations with a high risk of bleeding (eg, major abdominal
surgery), or, in the opinion of the Investigator, would otherwise require a
pre-operative platelet transfusion to prevent bleeding

Exclusion Criteria:

- Participant with a history of arterial or venous thrombosis within 6 months of
baseline;

- Participant with known portal vein blood flow velocity rate <10 cm/second or previous
portal vein thrombosis within 6 months of baseline;

- Participant plans to have a platelet transfusion or plans to receive blood products
containing platelets within 7 days of the Baseline Visit;

- Use of erythropoietin-stimulating agents;

- Participant has a known medical history of genetic prothrombotic syndromes; or

- Participant has abnormal hemoglobin levels or prothrombin time/international
normalized ratio